Le Lézard
Classified in: Environment, Health
Subjects: AWD, RCY, CSR, ENP

DaVita Medical Group Facility Awarded LEED® Gold Status



EL SEGUNDO, Calif., Sept. 13, 2017 /PRNewswire/ -- DaVita Medical Group, a division of DaVita Inc. (NYSE: DVA) and a leading independent medical group in the United States, today announced that its California headquarters facility has been awarded the Leadership in Energy & Environmental Design (LEED®) Gold certification by the U.S. Green Building Council (USGBC).

USGBC scores buildings in seven categories including sustainable sites, water efficiency, energy and atmosphere, materials and resources, indoor environmental quality, innovation in design and regional priority credits. Referred to as the Casa PacifiCA, in El Segundo, California, DaVita Medical Group's building received a Gold certification.

"We believe that being good stewards of our environment and our community are pivotal in our mission to build the leading independent medical group in America," said Jim McPhail, vice president of real estate and center development at DaVita. "By supporting a healthy environment and committing to sustainability we have the opportunity to improve health care in our community."  

Some building highlights of the Casa PacifiCA include:

DaVita, a national leader in sustainability efforts, is dedicated to its organizational initiative to pursue at least LEED® Silver certification for all business offices as part of the organization's 2020 environmental goals. The Casa PacifiCA certification, follows that of DaVita's World Headquarters in Denver, Colorado last year.

Learn more about DaVita's commitment to environmental sustainability for the future here.

About DaVita Medical Group
DaVita Medical Group is a division of DaVita Inc., a Fortune 500® company, that operates and manages medical groups and affiliated physician networks in California, Colorado, Florida, Nevada, New Mexico, Pennsylvania and Washington. A leading independent medical group in America, DaVita Medical Group has over two decades of experience providing coordinated, outcomes-based medical care in a cost-effective manner. DaVita Medical Group's teammates, employed clinicians and affiliated clinicians provided care for approximately 1.7 million patients. For more information, please visit DaVitaMedicalGroup.com.

About DaVita Inc.
DaVita Inc., a Fortune 500® company, is the parent company of DaVita Kidney Care and DaVita Medical Group. DaVita Kidney Care is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of June 30, 2017, DaVita Kidney Care operated or provided administrative services at 2,445 outpatient dialysis centers located in the United States serving approximately 194,600 patients. The company also operated 217 outpatient dialysis centers located in 11 countries outside the United States. DaVita Medical Group manages and operates medical groups and affiliated physician networks in California, Colorado, Florida, Nevada, New Mexico, Pennsylvania and Washington in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. DaVita Medical Group's teammates, employed clinicians and affiliated clinicians provided care for approximately 1.7 million patients. For more information, please visit DaVita.com/About.

Contact Information

Media:
Jessica Geurkink
(720) 925-3184
Jessica.Geurkink@davita.com         

DaVita Medical Group (PRNewsfoto/DaVita Medical Group)

 

SOURCE DaVita Medical Group


These press releases may also interest you

at 08:00
ViaCyte, Inc., a privately-held regenerative medicine company, today announced two-year data from Cohort 1 of the ongoing Safety, Tolerability, and Efficacy of VC-01tm (PEC-Encaptm) Product Candidate in Type One Diabetes (STEP ONE) clinical trial. ...

at 08:00
Amgen  today announced new data that show Repatha® (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with Type 2 diabetes and hypercholesterolemia or...

at 08:00
Two investigational doses of Lilly's dulaglutide (4.5 mg and 3.0 mg), as well as Trulicity® (dulaglutide) 1.5 mg, provided significantly better blood sugar control with weight benefits compared to placebo in adults with type 2 diabetes.1 Data from...

at 07:00
Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and...

at 06:00
The Ontario Nurses' Association (ONA) is celebrating Pride with style and professionalism, placing transit shelter ads featuring the faces of its LGBTQ+ members in four cities. "Ontario nurses are committed to every...

at 06:00
Xcode Life, an innovative personal genomics company has announced the worldwide launch of the South Asian Genome (SAGE) Project. This is open to all individuals with known South Asian roots. All individuals who qualify the eligibility criteria will...




News published on 13 september 2017 at 06:35 and distributed by: